176 related articles for article (PubMed ID: 21561916)
1. Single amino acid changes in the virus capsid permit coxsackievirus B3 to bind decay-accelerating factor.
Pan J; Narayanan B; Shah S; Yoder JD; Cifuente JO; Hafenstein S; Bergelson JM
J Virol; 2011 Jul; 85(14):7436-43. PubMed ID: 21561916
[TBL] [Abstract][Full Text] [Related]
2. Variations of coxsackievirus B3 capsid primary structure, ligands, and stability are selected for in a coxsackievirus and adenovirus receptor-limited environment.
Carson SD; Chapman NM; Hafenstein S; Tracy S
J Virol; 2011 Apr; 85(7):3306-14. PubMed ID: 21270163
[TBL] [Abstract][Full Text] [Related]
3. Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55).
Bergelson JM; Mohanty JG; Crowell RL; St John NF; Lublin DM; Finberg RW
J Virol; 1995 Mar; 69(3):1903-6. PubMed ID: 7531780
[TBL] [Abstract][Full Text] [Related]
4. Specificity of coxsackievirus B3 interaction with human, but not murine, decay-accelerating factor: replacement of a single residue within short consensus repeat 2 prevents virus attachment.
Pan J; Zhang L; Organtini LJ; Hafenstein S; Bergelson JM
J Virol; 2015 Jan; 89(2):1324-8. PubMed ID: 25392210
[TBL] [Abstract][Full Text] [Related]
5. The crystal structure of a coxsackievirus B3-RD variant and a refined 9-angstrom cryo-electron microscopy reconstruction of the virus complexed with decay-accelerating factor (DAF) provide a new footprint of DAF on the virus surface.
Yoder JD; Cifuente JO; Pan J; Bergelson JM; Hafenstein S
J Virol; 2012 Dec; 86(23):12571-81. PubMed ID: 22973031
[TBL] [Abstract][Full Text] [Related]
6. A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells.
Shafren DR; Williams DT; Barry RD
J Virol; 1997 Dec; 71(12):9844-8. PubMed ID: 9371658
[TBL] [Abstract][Full Text] [Related]
7. Mapping of the RD phenotype of the Nancy strain of coxsackievirus B3.
Lindberg AM; Crowell RL; Zell R; Kandolf R; Pettersson U
Virus Res; 1992 Jul; 24(2):187-96. PubMed ID: 1326828
[TBL] [Abstract][Full Text] [Related]
8. Genome of coxsackievirus B3.
Lindberg AM; Stålhandske PO; Pettersson U
Virology; 1987 Jan; 156(1):50-63. PubMed ID: 3027968
[TBL] [Abstract][Full Text] [Related]
9. Cytolytic replication of coxsackievirus B2 in CAR-deficient rhabdomyosarcoma cells.
Polacek C; Ekström JO; Lundgren A; Lindberg AM
Virus Res; 2005 Nov; 113(2):107-15. PubMed ID: 15964091
[TBL] [Abstract][Full Text] [Related]
10. Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21.
Johansson ES; Xing L; Cheng RH; Shafren DR
J Virol; 2004 Nov; 78(22):12603-12. PubMed ID: 15507647
[TBL] [Abstract][Full Text] [Related]
11. Interaction with coxsackievirus and adenovirus receptor, but not with decay-accelerating factor (DAF), induces A-particle formation in a DAF-binding coxsackievirus B3 isolate.
Milstone AM; Petrella J; Sanchez MD; Mahmud M; Whitbeck JC; Bergelson JM
J Virol; 2005 Jan; 79(1):655-60. PubMed ID: 15596863
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis of differential receptor usage for naturally occurring CD55-binding and -nonbinding coxsackievirus B3 strains.
Wang Q; Yang Q; Liu C; Wang G; Song H; Shang G; Peng R; Qu X; Liu S; Cui Y; Wang P; Xu W; Zhao X; Qi J; Yang M; Gao GF
Proc Natl Acad Sci U S A; 2022 Jan; 119(4):. PubMed ID: 35046043
[TBL] [Abstract][Full Text] [Related]
13. Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic differences to capsid protein VP1.
Schmidtke M; Selinka HC; Heim A; Jahn B; Tonew M; Kandolf R; Stelzner A; Zell R
Virology; 2000 Sep; 275(1):77-88. PubMed ID: 11017789
[TBL] [Abstract][Full Text] [Related]
14. Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection.
Newcombe NG; Johansson ES; Au G; Lindberg AM; Barry RD; Shafren DR
J Virol; 2004 Feb; 78(3):1431-9. PubMed ID: 14722298
[TBL] [Abstract][Full Text] [Related]
15. Interaction with decay-accelerating factor facilitates coxsackievirus B infection of polarized epithelial cells.
Shieh JT; Bergelson JM
J Virol; 2002 Sep; 76(18):9474-80. PubMed ID: 12186929
[TBL] [Abstract][Full Text] [Related]
16. Modelling of the tertiary structure of coxsackievirus B3 from the structure of poliovirus and rhinovirus.
Liljas L; Lindberg AM; Pettersson U
Scand J Infect Dis Suppl; 1993; 88():15-24. PubMed ID: 8390718
[TBL] [Abstract][Full Text] [Related]
17. A single amino acid substitution controls DAF-dependent phenotype of echovirus 11 in rhabdomyosarcoma cells.
Novoselov AV; Rezaykin AV; Sergeev AG; Fadeyev FA; Grigoryeva JV; Sokolova ZI
Virus Res; 2012 Jun; 166(1-2):87-96. PubMed ID: 22445689
[TBL] [Abstract][Full Text] [Related]
18. Study of Coxsackie B viruses interactions with Coxsackie Adenovirus receptor and Decay-Accelerating Factor using Human CaCo-2 cell line.
Riabi S; Harrath R; Gaaloul I; Bouslama L; Nasri D; Aouni M; Pillet S; Pozzetto B
J Biomed Sci; 2014 May; 21(1):50. PubMed ID: 24885774
[TBL] [Abstract][Full Text] [Related]
19. Altered receptor specificity of coxsackievirus B3 after growth in rhabdomyosarcoma cells.
Reagan KJ; Goldberg B; Crowell RL
J Virol; 1984 Mar; 49(3):635-40. PubMed ID: 6321753
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of Swine vesicular disease virus and implications for host adaptation.
Fry EE; Knowles NJ; Newman JW; Wilsden G; Rao Z; King AM; Stuart DI
J Virol; 2003 May; 77(9):5475-86. PubMed ID: 12692248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
